Our findings that CD206+ macrophage subsets are associated with good prognosis in breast cancer patients, while MHCII‐expressing CD206− macrophages are associated with a negative prognosis, are controversial based on existing literature for a number of reasons. This evidence concerns the gene MRC1 and breast carcinoma.